AskBio Enters Research Collaboration and Licensing Agreement with (UNC)

ASF Funded Research leads to a collaboration for gene therapy to correct deficiency in UBE3A gene

Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy company, entered into a research collaboration and licensing agreement with the University of North Carolina at Chapel Hill (UNC) for the development and commercialization of gene therapy for Angelman syndrome.

The UNC School of Medicine team, led by Ben Philpot, PhD, and Mark Zylka, PhD, has found preclinical evidence that gene therapy may help individuals with AS by dramatically improving seizure and motor outcomes.

The ASF is proud of its history funding the work on Dr. Philpot and Dr. Zylka that has lead to this collaboration.